Global Autoimmune Disease Diagnosis Market Size, Share, Growth & Trends Analysis Report By End User (Hospitals & Clinics, Diagnostic Laboratories, Research Institutes, Academic Centers) By Diagnostic Method (Laboratory Tests, Imaging, Molecular Diagnostics) And Regional Outlook, Growth Potential & Forecast 2024 – 2030

Autoimmune Disease Diagnosis Market Size Forecast 2024 – 2030 | TLM Research

Summary of Report:

The Global Autoimmune Disease Diagnosis Market was worth USD 5.23 billion in 2024 and is expected to grow to USD 8.29 billion by 2030, at a CAGR of 6.80% during the forecast period. The research looks at the market in terms of revenue in all of the key regions, which have been divided into countries.

Price

Licence: Single User

Licence: Multiple Users

Licence: Corporate User

Licence

Clear

Request Sample

Pre-Order Inquiry

Do You have any Budget constraints?
Simply Ask our Sales Team About it.

Request Discount

Description

Scope Global Autoimmune Disease Diagnosis Market

Numerous medical disciplines, including rheumatology, immunology, dermatology, gastroenterology, endocrinology, neurology, and more, may get involved in the treatment of autoimmune illnesses since they can impact several organs and systems in the body. The process of making a diagnosis frequently combines laboratory testing, imaging investigations, physical examinations, and medical histories. Antinuclear antibodies (ANA) and rheumatoid factor (RF) are two examples of blood tests used often to check for autoantibodies. Organ involvement can also be evaluated by using sophisticated imaging methods such as CT, MRI, and ultrasound studies. Technological developments such as molecular diagnostics and genetic sequencing are increasing the precision and efficacy of diagnosing autoimmune diseases. Utilizing these approaches, one may ascertain genetic susceptibilities and particular biomarkers linked to certain autoimmune diseases.

The Global Autoimmune Disease Diagnosis Market was worth USD 5.23 billion in 2024 and is expected to grow to USD 8.29 billion by 2030, at a CAGR of 6.80% during the forecast period. The research looks at the market in terms of revenue in all of the key regions, which have been divided into countries.

Autoimmune Disease Diagnosis Market: Impact of COVID – 19

Routine care was disrupted in many hospital systems during the pandemic as a result of the massive influx of COVID-19 patients, resource reallocation, and installation of infection control measures. Many patients experienced delays in diagnosis and treatment beginning as a result of non-urgent medical visits being often canceled or postponed, including those for the diagnosis and management of autoimmune diseases. Certain patients refrained from seeking medical assistance due to travel restrictions, lockdowns, and fear of contracting the virus, which resulted in a delayed diagnosis and worsened symptoms. Furthermore, those with autoimmune disorders, who frequently have impaired immune systems as a result of their conditions or treatments, would have experienced increased anxiety around the danger of contracting COVID-19 when visiting medical institutions.

Autoimmune Disease Diagnosis Market: Growth Drivers

Developments in Diagnostic technology: The precision and effectiveness of diagnosing autoimmune diseases are improved by ongoing developments in diagnostic technology, such as multiplex tests, genome sequencing, and biomarker discovery.
Growing Illness Prevalence: The need for diagnostic services is driven by the rising incidence of autoimmune illnesses throughout the world, which is linked to variables such genetic susceptibility, environmental triggers, and alterations in lifestyle.
Increasing Disease Awareness: As the public and medical community become more aware of autoimmune illnesses, symptoms can be recognized sooner, which facilitates faster diagnosis and treatment start.

Autoimmune Disease Diagnosis Market: Restraints

Limited Access to Healthcare: The availability of diagnostic testing for autoimmune illnesses is restricted in rural or underserved locations, which makes prompt diagnosis and treatment more difficult.
Diagnostic Difficulties: Autoimmune illnesses can resemble other ailments and frequently exhibit vague symptoms, making diagnosis difficult and perhaps delaying treatment.
High Cost of Diagnostic testing: For patients without sufficient insurance coverage or financial means, the high cost of certain diagnostic testing for autoimmune illnesses may be a barrier to access.

Autoimmune Disease Diagnosis Market: Opportunity Factors

Personalized Medicine Approaches: The move toward customized treatment plans and personalized medicine opens doors for the creation of companion diagnostic tests that can direct care decisions according to unique patient traits.
Innovations in Technology: The accessibility, precision, and cost-effectiveness of diagnosing autoimmune diseases might be enhanced by ongoing technological advancements including wearable technology, point-of-care testing, and AI-driven diagnostics.
Emerging Markets: As a result of bettering healthcare infrastructure and raising illness awareness, untapped markets in emerging nations provide potential for market expansion and growth in the diagnosis of autoimmune diseases.

Autoimmune Disease Diagnosis Market: Challenges

Conflict with Additional Conditions: Clinical characteristics of autoimmune disorders are frequently shared with other inflammatory or infectious ailments, making differential diagnosis more difficult and requiring a thorough examination by medical professionals.
Data Security and Privacy Issues: Concerns regarding data privacy and security are brought up by the growing use of digital health solutions and patient data for diagnostic reasons. This calls for strong regulatory frameworks and adherence to ethical norms.
Diagnostic Delays and Misdiagnosis: Due to their vague symptoms, autoimmune illnesses frequently result in diagnostic delays and misdiagnoses, which prolong patient suffering and may cause irreparable harm to afflicted organs.

Autoimmune Disease Diagnosis Market: Recent Developments

Bio-Rad Laboratories: On Bio-Rad Laboratories, Inc. renowned for its advancements in life science research and clinical diagnostic solutions, has unveiled its inaugural ultrasensitive multiplexed digital PCR assay, known as the ddPLEX ESR1 Mutation Detection Kit.

Key Outcomes of the Report

Analysis of important participants in the autoimmune disease diagnosis market, including diagnostic businesses, pharmaceutical corporations involved in diagnostics, and research organizations. This covers their major goods, market share, and most recent advancements. insights into the latest technical developments in the detection of autoimmune diseases, including point-of-care diagnostics, multiplex assays, next-generation sequencing, and digital health solutions. Analyzing market trends and prospects in various locations while taking the regulatory framework, illness prevalence, and healthcare infrastructure into account. Finding the drivers of the market’s expansion disease prevalence rising, need for customized treatment rising, technological developments in diagnostics as well as the obstacles high prices, regulatory obstacles, and delays in diagnosis that the market faces.

List of Key Players in the Global Autoimmune Disease Diagnosis Market:

Quest Diagnostics
Laboratory Corporation of America Holdings (LabCorp)
Euroimmun AG
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
Siemens Healthineers
Abbott Laboratories
Roche Diagnostics

Autoimmune Disease Diagnosis Market: Segmentation

By Diagnostic Method

Laboratory Tests
Imaging
Molecular Diagnostics

By Autoimmune Disease Type

Rheumatoid Arthritis
Systemic Lupus Erythematosus (SLE)
Multiple Sclerosis (MS)
Type 1 Diabetes
Inflammatory Bowel Disease (IBD) (e.g., Crohn’s disease, ulcerative colitis)
Psoriasis
Hashimoto’s Thyroiditis

By End-User

Hospitals & Clinics
Diagnostic Laboratories
Research Institutes
Academic Centers

By Technology

Conventional Tests
Advanced Molecular Diagnostics
Point-of-Care Testing

By Sales Channel

Direct Sales
Distributor Sales

By Patient Age Group

Pediatric
Adult
Geriatric
Type of Biomarkers
Autoantibodies
Genetic Markers
Cytokines and Chemokines

By Region

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Table of Content

1 Executive Summary
1.1 Introduction of Autoimmune Disease Diagnosis
1.2 COVID-19 Impacts on Autoimmune Disease Diagnosis Industry
2 Autoimmune Disease Diagnosis Market – Product Analysis
2.1 Global Autoimmune Disease Diagnosis Market – Product Overview
2.2 Global Autoimmune Disease Diagnosis Market, by Product, 2017-2029 (USD Million)
2.3 Consumables & Assay Kits
2.03.01 Global Autoimmune Disease Diagnosis Market For Consumables & Assay Kits, 2017 – 2029 (USD Million)
2.4 Instruments
2.04.01 Global Autoimmune Disease Diagnosis Market For Instruments, 2017 – 2029 (USD Million)
2.5 Services
2.05.01 Global Autoimmune Disease Diagnosis Market For Services, 2017 – 2029 (USD Million)
0.00.00 Autoimmune Disease Diagnosis Market – Test Type Analysis
2.24.00 Global Autoimmune Disease Diagnosis Market – Test Type Overview
4.48.00 Antinuclear Antibody Tests
3.02.01 Global Autoimmune Disease Diagnosis Market For Antinuclear Antibody Tests, 2017 – 2029 (USD Million)
7.12.00 Autoantibody Tests
3.03.01 Global Autoimmune Disease Diagnosis Market For Autoantibody Tests, 2017 – 2029 (USD Million)
3.4 Complete Blood Count (CBC)
3.04.01 Global Autoimmune Disease Diagnosis Market For Complete Blood Count (CBC), 2017 – 2029 (USD Million)
12.00.00 C-reactive Protein (CRP)
3.05.01 Global Autoimmune Disease Diagnosis Market For C-reactive Protein (CRP), 2017 – 2029 (USD Million)
14.24.00 Urinalysis
3.06.01 Global Autoimmune Disease Diagnosis Market For Urinalysis, 2017 – 2029 (USD Million)
3.7 Others Tests
3.07.01 Global Autoimmune Disease Diagnosis Market For Others Tests, 2017 – 2029 (USD Million)
0.00.00 Autoimmune Disease Diagnosis Market – Target Disease Analysis
2.24.00 Global Autoimmune Disease Diagnosis Market – Target Disease Overview
4.48.00 Systemic Autoimmune Disease
4.02.01 Global Autoimmune Disease Diagnosis Market For Systemic Autoimmune Disease, 2017 – 2029 (USD Million)
4.02.02 Systemic Autoimmune Disease Market, by Type
4.2.2.1 Rheumatoid Arthritis
4.2.2.2 Psoriasis
4.2.2.3 Systemic Lupus Erythematosus
4.2.2.4 Multiple Sclerosis
4.2.2.5 Others
7.12.00 Localized Autoimmune Disease
4.03.01 Global Autoimmune Disease Diagnosis Market For Localized Autoimmune Disease, 2017 – 2029 (USD Million)
4.03.01 Localized Autoimmune Disease, by Type
4.3.1.1 Inflammatory Bowel Disease
4.3.1.2 Type 1 Diabetes
4.3.1.3 Thyroid
4.3.1.4 Other
0.00.00 Autoimmune Disease Diagnosis Market – End User Analysis
2.24.00 Global Autoimmune Disease Diagnosis Market – End User Overview
4.48.00 Clinical Laboratories
5.02.01 Global Autoimmune Disease Diagnosis Market For Clinical Laboratories, 2017 – 2029 (USD Million)
7.12.00 Hospitals
5.03.01 Global Autoimmune Disease Diagnosis Market For Hospitals, 2017 – 2029 (USD Million)
9.36.00 Research Laboratories & Institutes
5.04.01 Global Autoimmune Disease Diagnosis Market For Research Laboratories & Institutes, 2017 – 2029 (USD Million)
12.00.00 Others
5.05.01 Global Autoimmune Disease Diagnosis Market For Others, 2017 – 2029 (USD Million)
6 Autoimmune Disease Diagnosis Market – Regional Analysis
6.1 Global Autoimmune Disease Diagnosis Market Regional Overview
4.48.00 Global Autoimmune Disease Diagnosis Market Share, by Region, 2020 & 2029 (USD Million)
6.3 North America
6.03.01 North America Autoimmune Disease Diagnosis Market, 2017 – 2029 (USD Million)
6.03.02 North America Autoimmune Disease Diagnosis Market, by Country, 2017 – 2029 (USD Million)
6.03.03 North America Autoimmune Disease Diagnosis Market, by Product, 2017 – 2029
6.03.04 North America Autoimmune Disease Diagnosis Market, by Test Type, 2017 – 2029
6.03.05 North America Autoimmune Disease Diagnosis Market, by Target Disease, 2017 – 2029
6.03.06 North America Autoimmune Disease Diagnosis Market, by End User, 2017 – 2029
6.03.07 U.S.
6.3.7.1 By Product, 2017 – 2029
6.3.7.2 By Test Type
6.3.7.3 By Target Disease
6.3.7.4 By End User
6.03.08 Canada
6.3.8.1 By Product, 2017 – 2029
6.3.8.2 By Test Type
6.3.8.3 By Target Disease
6.3.8.4 By End User
6.03.09 Mexico
6.3.9.1 By Product, 2017 – 2029
6.3.9.2 By Test Type
6.3.9.3 By Target Disease
6.3.9.4 By End User
6.4 Europe
6.04.01 Europe Autoimmune Disease Diagnosis Market, 2017 – 2029 (USD Million)
6.04.02 Europe Autoimmune Disease Diagnosis Market, by Country, 2017 – 2029 (USD Million)
6.04.03 Europe Autoimmune Disease Diagnosis Market, by Product, 2017 – 2029
6.04.04 Europe Autoimmune Disease Diagnosis Market, by Test Type, 2017 – 2029
6.04.05 Europe Autoimmune Disease Diagnosis Market, by Target Disease, 2017 – 2029
6.04.06 Europe Autoimmune Disease Diagnosis Market, by End User, 2017 – 2029
6.04.07 Germany
6.4.7.1 By Product, 2017 – 2029
6.4.7.2 By Test Type
6.4.7.3 By Target Disease
6.4.7.4 By End User
6.04.08 France
6.4.8.1 By Product, 2017 – 2029
6.4.8.2 By Test Type
6.4.8.3 By Target Disease
6.4.8.4 By End User
6.04.09 U.K
6.4.9.1 By Product, 2017 – 2029
6.4.9.2 By Test Type
6.4.9.3 By Target Disease
6.4.9.4 By End User
6.04.10 Italy
6.4.10.1 By Product, 2017 – 2029
6.4.10.2 By Test Type
6.4.10.3 By Target Disease
6.4.10.4 By End User
6.04.11 Spain
6.4.11.1 By Product, 2017 – 2029
6.4.11.2 By Test Type
6.4.11.3 By Target Disease
6.4.11.4 By End User
6.04.12 Rest of Europe
6.4.12.1 By Product, 2017 – 2029
6.4.12.2 By Test Type
6.4.12.3 By Target Disease
6.4.12.4 By End User
6.5 Asia Pacific
6.05.01 Asia Pacific Autoimmune Disease Diagnosis Market, 2017 – 2029 (USD Million)
6.05.02 Asia Pacific Autoimmune Disease Diagnosis Market, by Country, 2017 – 2029 (USD Million)
6.05.03 Asia Pacific Autoimmune Disease Diagnosis Market, by Product, 2017 – 2029
6.05.04 Asia Pacific Autoimmune Disease Diagnosis Market, by Test Type, 2017 – 2029
6.05.05 Asia Pacific Autoimmune Disease Diagnosis Market, by Target Disease, 2017 – 2029
6.05.06 Asia Pacific Autoimmune Disease Diagnosis Market, by End User, 2017 – 2029
6.05.07 China
6.5.7.1 By Product, 2017 – 2029
6.5.7.2 By Test Type
6.5.7.3 By Target Disease
6.5.7.4 By End User
6.05.08 India
6.5.8.1 By Product, 2017 – 2029
6.5.8.2 By Test Type
6.5.8.3 By Target Disease
6.5.8.4 By End User
6.05.09 JAPAN
6.5.9.1 By Product, 2017 – 2029
6.5.9.2 By Test Type
6.5.9.3 By Target Disease
6.5.9.4 By End User
6.05.10 Southeast Asia
6.5.10.1 By Product, 2017 – 2029
6.5.10.2 By Test Type
6.5.10.3 By Target Disease
6.5.10.4 By End User
6.05.11 Korea
6.5.11.1 By Product, 2017 – 2029
6.5.11.2 By Test Type
6.5.11.3 By Target Disease
6.5.11.4 By End User
6.05.12 Rest of Asia Pacific
6.5.12.1 By Product, 2017 – 2029
6.5.12.2 By Test Type
6.5.12.3 By Target Disease
6.5.12.4 By End User
6.6 SAMEA
6.06.01 SAMEA Autoimmune Disease Diagnosis Market, 2017 – 2029 (USD Million)
6.06.02 SAMEA Autoimmune Disease Diagnosis Market, by Country, 2017 – 2029 (USD Million)
6.06.03 SAMEA Autoimmune Disease Diagnosis Market, by Product, 2017 – 2029
6.06.04 SAMEA Autoimmune Disease Diagnosis Market, by Test Type, 2017 – 2029
6.06.05 SAMEA Autoimmune Disease Diagnosis Market, by Target Disease, 2017 – 2029
6.06.06 SAMEA Autoimmune Disease Diagnosis Market, by End User, 2017 – 2029
6.06.07 The Middle East & Africa
6.6.7.1 By Product, 2017 – 2029
6.6.7.2 By Test Type
6.6.7.3 By Target Disease
6.6.7.4 By End User
6.06.08 Brazil
6.6.8.1 By Product, 2017 – 2029
6.6.8.2 By Test Type
6.6.8.3 By Target Disease
6.6.8.4 By End User
6.06.09 REST OF SAMEA
6.6.9.1 By Product, 2017 – 2029
6.6.9.2 By Test Type
6.6.9.3 By Target Disease
6.6.9.4 By End User
7 Company Profiles
7.1 Abbott Laboratories
7.01.01 Company Description
7.1.1.1 Operations
7.1.1.2 Geographic Reach
7.1.1.3 Sales and Marketing
7.01.02 Financial Performance
7.01.03 Product Portfolio
7.01.04 Strategy
7.01.05 Key Development
4.48.00 BioMérieux SA
7.02.01 Company Description
7.2.1.1 Operations
7.2.1.2 Geographic Reach
7.2.1.3 Sales and Marketing
7.02.02 Financial Performance
7.02.03 Product Portfolio
7.02.04 Strategy
7.02.05 Mergers and Acquisitions
7.3 Bio-Rad Laboratories
7.03.01 Company Description
7.3.1.1 Operations
7.3.1.2 Geographic Reach
7.3.1.3 Sales and Marketing
7.03.02 Financial Performance
7.03.03 Product Portfolio
7.03.04 Strategy
7.03.05 Mergers and Acquisitions
9.36.00 PerkinElmer
7.04.01 Company Description
7.4.1.1 Operations
7.4.1.2 Geographic Reach
7.4.1.3 Sales and Marketing
7.04.02 Financial Performance
7.04.03 Product Portfolio
7.04.04 Strategy
7.04.05 Mergers and Acquisitions
12.00.00 F Hoffmann-La Roche Ltd
7.05.01 Company Description
7.5.1.1 Operations
7.5.1.2 Geographic Reach
7.5.1.3 Sales and Marketing
7.05.02 Financial Performance
7.05.03 Product Portfolio
7.05.04 Strategy
7.05.05 Mergers and Acquisitions
14.24.00 Siemens Healthcare GmbH
7.06.01 Company Description
7.6.1.1 Operations
7.6.1.2 Geographic Reach
7.6.1.3 Sales and Marketing
7.06.02 Financial Performance
7.06.03 Product Portfolio
7.06.04 Strategy
7.06.05 Mergers and Acquisitions
7.7 Thermo Fisher Scientific
7.07.01 Company Description
7.7.1.1 Operations
7.7.1.2 Geographic Reach
7.7.1.3 Sales and Marketing
7.07.02 Financial Performance
7.07.03 Product Portfolio
7.07.04 Strategy
7.07.05 Mergers and Acquisitions
7.8 Inova Diagnostics Inc.
7.08.01 Company Description
7.08.02 Product Portfolio
7.08.03 Key Development
7.9 Myriad Genetics Inc
7.09.01 Company Description
7.09.02 Financial Performance
7.09.03 Product Portfolio
7.09.04 Strategies
7.09.05 Key Development
7.1 Trinity Biotech Plc
7.10.01 Company Description
7.10.02 Financial Performance
7.10.03 Product Portfolio
7.10.04 Strategies
8 Autoimmune Disease Diagnosis — Industry Analysis
8.1 Market Drivers
8.01.01 Growing Burden Of Autoimmune Diseases And Rising Public Awareness
8.01.02 Technological Advancements And Improved Laboratory Automation
8.2 Market Restraints
8.02.01 Slow Turnaround Time Of Results And Need For Multiple Diagnostic Tests
8.02.02 High Cost and Reimbursement Issues Coupled With Regulatory Uncertainties
8.3 Market Opportunities and Future Trends
8.4 Porter’s Five Forces Analysis
8.04.01 Bargaining Power of Suppliers
8.04.02 Bargaining Power of Buyers
8.04.03 Threat of Substitute
8.04.04 Threat of New Entrants
8.04.05 Competitive Rivalry

Tables and Figures

List of Tables

TABLE 1 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029(USD MILLION)

TABLE 2 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029(USD MILLION)

TABLE 3 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029(USD MILLION)

TABLE 4 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER , 2017 – 2029(USD MILLION)

TABLE 5 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY REGION, 2017 – 2029 (USD MILLION)

TABLE 6 NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY COUNTRY, 2017 – 2029 (USD MILLION)

TABLE 7 NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 8 NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 9 NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 10 NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 11 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 12 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 13 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 14 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 15 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 16 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 17 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 18 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 19 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 20 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 21 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 22 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 23 EUROPE AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY COUNTRY, 2017 – 2029 (USD MILLION)

TABLE 24 EUROPE AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 25 EUROPE AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 26 EUROPE AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 27 EUROPE AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 28 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 29 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 30 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 31 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 32 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 33 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 34 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 35 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 36 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 37 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 38 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 39 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 40 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 41 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 42 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 43 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 44 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 45 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 46 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 47 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 48 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 49 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 50 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 51 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 52 ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY COUNTRY, 2017 – 2029 (USD MILLION)

TABLE 53 ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 54 ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 55 ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 56 ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 57 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 58 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 59 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 60 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 61 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 62 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 63 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 64 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 65 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 66 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 67 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 68 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 69 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 70 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 71 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 72 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 73 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 74 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 75 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 76 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 77 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 78 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 79 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 80 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 81 SAMEA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY COUNTRY, 2017 – 2029 (USD MILLION)

TABLE 82 SAMEA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 83 SAMEA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 84 SAMEA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 85 SAMEA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 86 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 87 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 88 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 89 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 90 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 91 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 92 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 93 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 94 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2017 – 2029 (USD MILLION)

TABLE 95 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2017 – 2029 (USD MILLION)

TABLE 96 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TARGET DISEASE, 2017 – 2029 (USD MILLION)

TABLE 97 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2017 – 2029 (USD MILLION)

TABLE 98 MARKET DRIVERS – IMPACT ANALYSIS

TABLE 99 MARKET RESTRAINTS

List of Figures

FIGURE 1 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET, 2017 – 2029 (USD MILLION)

FIGURE 2 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR CONSUMABLES & ASSAY KITS, 2017 – 2029 (USD MILLION)

FIGURE 3 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR INSTRUMENTS, 2017 – 2029 (USD MILLION)

FIGURE 4 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR SERVICES, 2017 – 2029 (USD MILLION)

FIGURE 5 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR ANTINUCLEAR ANTIBODY TESTS, 2017 – 2029 (USD MILLION)

FIGURE 6 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR AUTOANTIBODY TESTS, 2017 – 2029 (USD MILLION)

FIGURE 7 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR COMPLETE BLOOD COUNT (CBC), 2017 – 2029 (USD MILLION)

FIGURE 8 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR C-REACTIVE PROTEIN (CRP), 2017 – 2029 (USD MILLION)

FIGURE 9 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR URINALYSIS, 2017 – 2029 (USD MILLION)

FIGURE 10 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR OTHERS TESTS, 2017 – 2029 (USD MILLION)

FIGURE 11 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR SYSTEMIC AUTOIMMUNE DISEASE, 2017 – 2029 (USD MILLION)

FIGURE 12 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR LOCALIZED AUTOIMMUNE DISEASE, 2017 – 2029 (USD MILLION)

FIGURE 13 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, 2017 – 2029 (USD MILLION)

FIGURE 14 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR HOSPITALS, 2017 – 2029 (USD MILLION)

FIGURE 15 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR RESEARCH LABORATORIES & INSTITUTES, 2017 – 2029 (USD MILLION)

FIGURE 16 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR OTHERS, 2017 – 2029 (USD MILLION)

FIGURE 17 GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET SHARE, BY REGION, 2020 & 2029 (%)

FIGURE 18 NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, 2017 – 2029 (USD MILLION)

FIGURE 19 EUROPE AUTOIMMUNE DISEASE DIAGNOSIS MARKET, 2017 – 2029 (USD MILLION)

FIGURE 20 ASIA PACIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET, 2017 – 2029 (USD MILLION)

FIGURE 21 SAMEA AUTOIMMUNE DISEASE DIAGNOSIS MARKET, 2017 – 2029 (USD MILLION)

Frequently Asked Questions

Which autoimmune illnesses are common?

Rheumatoid arthritis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease (Ulcerative colitis and Crohn's disease), psoriasis, and Hashimoto's thyroiditis are a few common autoimmune disorders.
How can autoimmune illnesses get identified?

A patient's medical history, physical examination, laboratory testing (such as blood tests for autoantibodies), imaging investigations (such as MRI or CT scans), and occasionally tissue samples are used in the diagnosis process.
What signs and symptoms accompany autoimmune illnesses?

Depending on the particular autoimmune illness, symptoms might vary greatly, but they may include neurological symptoms, rash, fever, exhaustion, joint pain, muscular weakness, and digestive problems.